Viridian Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.76 Insider Own1.70% Shs Outstand26.13M Perf Week-2.46%
Market Cap318.97M Forward P/E- EPS next Y-3.37 Insider Trans-22.84% Shs Float18.72M Perf Month-11.86%
Income-86.60M PEG- EPS next Q-0.90 Inst Own91.70% Short Float7.98% Perf Quarter-42.13%
Sales1.70M P/S187.63 EPS this Y78.60% Inst Trans6.98% Short Ratio4.59 Perf Half Y-47.29%
Book/sh2.09 P/B5.12 EPS next Y10.20% ROA-47.70% Target Price33.11 Perf Year-40.22%
Cash/sh5.89 P/C1.82 EPS next 5Y- ROE-360.70% 52W Range9.47 - 22.00 Perf YTD-45.88%
Dividend- P/FCF- EPS past 5Y56.40% ROI-147.90% 52W High-51.36% Beta1.14
Dividend %- Quick Ratio12.50 Sales past 5Y-3.10% Gross Margin- 52W Low12.99% ATR0.98
Employees50 Current Ratio12.50 Sales Q/Q-86.70% Oper. Margin- RSI (14)43.23 Volatility9.96% 9.21%
OptionableYes Debt/Eq0.00 EPS Q/Q66.20% Profit Margin- Rel Volume0.52 Prev Close11.57
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume325.36K Price10.70
Recom1.40 SMA20-4.58% SMA50-12.77% SMA200-36.81% Volume168,141 Change-7.52%
Jun-23-22Initiated B. Riley Securities Buy $25
Nov-18-21Initiated SVB Leerink Outperform $32
Oct-12-21Initiated Evercore ISI Outperform $40
Jan-25-21Initiated Ladenburg Thalmann Buy $40
Jun-23-22 07:00AM  
Jun-03-22 08:00AM  
Jun-01-22 08:00AM  
May-12-22 04:05PM  
May-03-22 08:00AM  
Apr-06-22 08:00AM  
Apr-04-22 04:05PM  
Mar-21-22 04:05PM  
Mar-14-22 06:36PM  
Mar-10-22 04:05PM  
Mar-03-22 04:16PM  
Feb-14-22 08:00AM  
Jan-31-22 07:00AM  
Jan-04-22 07:00AM  
Dec-20-21 07:00AM  
Nov-30-21 08:00AM  
Nov-15-21 07:00AM  
Nov-04-21 04:05PM  
Nov-03-21 04:05PM  
Oct-14-21 08:00AM  
Sep-30-21 08:06AM  
Sep-23-21 04:01PM  
Sep-21-21 12:22AM  
Sep-20-21 04:01PM  
Aug-23-21 02:36PM  
Aug-11-21 07:00AM  
Aug-05-21 08:30AM  
Jul-26-21 07:30AM  
Jul-15-21 04:05PM  
Jul-14-21 08:00AM  
Jul-07-21 08:00AM  
Jun-10-21 08:00AM  
May-24-21 10:45AM  
May-14-21 08:00AM  
May-06-21 04:05PM  
Mar-25-21 04:05PM  
Mar-23-21 04:00AM  
Mar-09-21 04:30PM  
Feb-22-21 08:00AM  
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Violin JonathanChief Executive OfficerJun 01Sale12.2030,000366,000480,905Jun 02 05:29 PM
Violin JonathanChief Executive OfficerMay 02Sale13.0430,000391,200510,905May 04 05:23 PM
Violin JonathanChief Executive OfficerApr 04Sale18.933,60068,148540,905Apr 05 06:09 PM
Violin JonathanChief Executive OfficerApr 01Sale18.9226,400499,488544,505Apr 05 06:09 PM
Violin JonathanChief Executive OfficerMar 02Sale17.3611,106192,800570,905Mar 03 04:48 PM
Violin JonathanChief Executive OfficerMar 01Sale17.8218,894336,691582,011Mar 03 04:48 PM
Violin JonathanChief Executive OfficerFeb 03Sale19.1690917,416600,905Feb 03 06:11 PM
Violin JonathanChief Executive OfficerFeb 02Sale18.4712,340227,920601,814Feb 03 06:11 PM
Violin JonathanChief Executive OfficerFeb 01Sale19.5516,751327,482614,154Feb 03 06:11 PM
Frazier Life Sciences Public F10% OwnerSep 23Buy11.00200,0002,200,0001,505,200Sep 28 07:46 PM
Fairmount Funds Management LLCDirectorSep 21Buy11.00909,0009,999,000938,233Sep 23 09:30 AM